CA2372907A1 - Systeme d'activation du zymogene - Google Patents

Systeme d'activation du zymogene Download PDF

Info

Publication number
CA2372907A1
CA2372907A1 CA002372907A CA2372907A CA2372907A1 CA 2372907 A1 CA2372907 A1 CA 2372907A1 CA 002372907 A CA002372907 A CA 002372907A CA 2372907 A CA2372907 A CA 2372907A CA 2372907 A1 CA2372907 A1 CA 2372907A1
Authority
CA
Canada
Prior art keywords
seq
protease
pro
sequence
artificial sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002372907A
Other languages
English (en)
Inventor
Andrew Darrow
Jensen Qi
Patricia Andrade-Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Mcneil Pharmaceutical Research Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2372907A1 publication Critical patent/CA2372907A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne les séquences d'ADN codant un système de vecteurs d'expression qui permettra, grâce à une protéolyse limitée, l'activation du précurseur zymogène exprimé de protéases de la sérine (S1) d'une manière reproductible et hautement contrôlée. Traitée, la protéine exprimée, une fois activée, est rendue dans une forme appropriée pour mesurer l'activité catalytique, laquelle, sous la forme activée, est souvent une représentation plus précise du produit génique de la protéase S1 mature par rapport au précurseur zymogène non traité. Cette série de constructions d'activation zymogène représente donc un système important d'analyse et de caractérisation de produits géniques de la protéase de la sérine.
CA002372907A 1999-04-30 2000-04-13 Systeme d'activation du zymogene Abandoned CA2372907A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30316299A 1999-04-30 1999-04-30
US09/303,162 1999-04-30
PCT/US2000/009973 WO2000066709A2 (fr) 1999-04-30 2000-04-13 Systeme d'activation du zymogene

Publications (1)

Publication Number Publication Date
CA2372907A1 true CA2372907A1 (fr) 2000-11-09

Family

ID=23170790

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002372907A Abandoned CA2372907A1 (fr) 1999-04-30 2000-04-13 Systeme d'activation du zymogene

Country Status (6)

Country Link
EP (1) EP1173590A4 (fr)
JP (1) JP2003531567A (fr)
AR (1) AR023818A1 (fr)
AU (1) AU4239600A (fr)
CA (1) CA2372907A1 (fr)
WO (1) WO2000066709A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006271285A (ja) * 2005-03-30 2006-10-12 National Institute Of Information & Communication Technology 改良型ｈａタグ及び改良型ｈａタグを用いたスクリーニング方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200340A (en) * 1987-05-22 1993-04-06 Zymogenetics, Inc. Thrombin-activated tissue plasminogen activators
US5504001A (en) * 1987-11-25 1996-04-02 Zymogenetics, Inc. Hybrid plasminogen activator
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5196322A (en) * 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
US5342762A (en) * 1991-01-03 1994-08-30 Wisconsin Alumni Research Foundation Fibronectin purification vector
ATE242330T1 (de) * 1993-01-15 2003-06-15 Inst Genetics Llc Klonierung von enterokinase und verfahren zu deren verwendung
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US6277618B1 (en) * 1996-06-06 2001-08-21 Roche Diagnostics Gmbh Recombinant blood-coagulation proteases
AU742794B2 (en) * 1997-04-25 2002-01-10 Sembiosys Genetics Inc. Method for cleavage of fusion proteins

Also Published As

Publication number Publication date
EP1173590A2 (fr) 2002-01-23
AU4239600A (en) 2000-11-17
EP1173590A4 (fr) 2003-01-15
JP2003531567A (ja) 2003-10-28
AR023818A1 (es) 2002-09-04
WO2000066709A9 (fr) 2002-08-29
WO2000066709A2 (fr) 2000-11-09
WO2000066709A3 (fr) 2001-02-15

Similar Documents

Publication Publication Date Title
Collins-Racie et al. Production of recombinant bovine enterokinase catalytic subunit in Escherichia coli using the novel secretory fusion partner DsbA
Kiefer et al. Identification of a second human subtilisin-like protease gene in the fes/fps region of chromosome 15
Benjannet et al. Comparative biosynthesis, covalent post-translational modifications and efficiency of prosegment cleavage of the prohormone convertases PC1 and PC2: glycosylation, sulphation and identification of the intracellular site of prosegment cleavage of PC1 and PC2
Seidah et al. Mammalian neural and endocrine pro-protein and pro-hormone convertases belonging to the subtilisin family of serine proteinases
EP1127154B1 (fr) Technique de production du facteur vii
US6331427B1 (en) Protease homologs
CZ298298B6 (cs) Analogy faktoru X s modifikovanými štepnými místyproteas, preparáty tyto látky obsahující, jejich použití a zpusob jejich výroby
US6750034B1 (en) DNA encoding human serine protease D-G
US6420157B1 (en) Zymogen activation system
Rehemtulla et al. Protein processing within the secretory pathway
ZA200504958B (en) Use of caspase enzymes for maturation of engineered recombinant polypeptidew fusions
Gensberg et al. Subtilisin-related serine proteases in the mammalian constitutive secretory pathway
CA2301698A1 (fr) Precurseurs zymogenes de proteases activables par voie autocatalytique et leur utilisation
EP2308901B1 (fr) Clivage des protéines de fusion à l'aide de la protéase granzyme B
CA2372907A1 (fr) Systeme d'activation du zymogene
CA2387291A1 (fr) Adn codant la serine protease t humaine
AU2009307423B2 (en) Process for producing protein capable of forming inclusion body
Nakayama [12] Purification of recombinant soluble forms of furin produced in chinese hamster ovary cells
Tippett Substrate Specificity of the Widely Expressed Subtilisin-like Proprotein Convertases (SPCs): A Role for the Substrate Amino Acid Directly Downstream of the Endoproteolytic Cleavage Site
Wüthrich et al. Human lactase-phlorizin hydrolase is not processed by furin, PC1/PC3, PC2, PACE4 and PC5/PC6A of the family of subtilisin-like proprotein processing proteases
Subramani Substrate Specificity of the Widely Expressed Subtilisin-like Proprotein Convertases

Legal Events

Date Code Title Description
FZDE Dead